Bruker (NASDAQ:BRKR) Stock Price Expected to Rise, Leerink Partners Analyst Says

Bruker (NASDAQ:BRKR) had its target price hoisted by equities research analysts at Leerink Partners from $80.00 to $85.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Leerink Partners‘s price target points to a potential upside of 46.40% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. TD Cowen raised their price objective on Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Guggenheim boosted their target price on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Stifel Nicolaus set a $50.00 target price on Bruker in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. lowered Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research report on Wednesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $59.79.

Bruker Stock Down 9.0%

Shares of NASDAQ BRKR traded down $5.73 during mid-day trading on Thursday, reaching $58.06. 3,223,548 shares of the company were exchanged, compared to its average volume of 2,379,493. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The stock has a market cap of $8.85 billion, a price-to-earnings ratio of -82.94, a P/E/G ratio of 1.73 and a beta of 1.26. Bruker has a 1 year low of $32.37 and a 1 year high of $68.98. The firm has a 50-day moving average of $58.95 and a 200 day moving average of $50.48.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The company had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same quarter last year, the company earned $0.45 earnings per share. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. On average, research analysts expect that Bruker will post 2.12 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BRKR. Essential Partners LLC purchased a new stake in shares of Bruker in the first quarter valued at about $36,000. Global Retirement Partners LLC purchased a new position in Bruker during the second quarter worth about $38,000. Provenance Wealth Advisors LLC acquired a new position in Bruker in the 3rd quarter valued at about $52,000. EverSource Wealth Advisors LLC boosted its holdings in Bruker by 532.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 1,263 shares during the last quarter. Finally, Root Financial Partners LLC acquired a new position in Bruker in the 3rd quarter valued at about $57,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 adjusted earnings of $0.56 per share, above the $0.42 consensus, and revenue of $874 million versus estimates of about $865 million. Revenue rose 1.6% year over year. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management highlighted margin expansion and strong bookings, and said U.S. academic demand returned in Q3. The company also sees potential for double-digit EPS growth in fiscal 2027, although that outlook is forward-looking. Bruker Q3 2026 Earnings Call Highlights
• Neutral Sentiment: Bruker forecast 2026 revenue of $3.52 billion to $3.56 billion, compared with a FactSet estimate of $3.56 billion. Its adjusted EPS range of $2.10 to $2.15 broadly brackets the $2.12 estimate. Bruker 2026 Revenue Outlook
• Negative Sentiment: The outlook offered little upside to expectations, while coverage also flagged a steep goodwill charge that weighed on reported results. These concerns may have overshadowed the quarterly beat and contributed to the weaker share performance. Bruker Q3 2026: Margin Surge Masks a Steep Goodwill Charge

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.